One in six Australian couples will have a fertility issue at some point in their lives and one in 10 couples will have trouble conceiving their second child. You are not alone.
Don’t panic, your fertility journey doesn’t have to be an express service straight to IVF. Some simple changes can improve your chance of conceiving naturally.
It's important to remember the emotions, worries and thoughts you are currently trying to deal with are valid and common. You are not alone. Read on
Looking for a range of fertility calculators, images, downloads and ebooks regarding fertility? Our Fertility tools are designed to help you.
The World Health Organisation predicts that infertility will be the third most serious health condition in the 21st Century
We're dedicated to helping you achieve your dream - having a baby. We offer a range of services - from IVF to genetic diagnosis of pre-implantation embryos - all with the aim of easing your journey to successful pregnancy.
Are you a female struggling to conceive? Read through potential reasons why, or learn more about testing options.
With 40% of fertility issues being male related, find out what may be causing you troubles, or learn more about male fertility testing
Genea has a comprehensive suite of genetic screening and testing based on 30 years of leading fertility science. Empower yourself with our preconception through to prenatal testing.
Our intention, driven by 30 years of planning, compassion and research investment, is to put our words into action for you by providing access to high success rates.
Because of the care, technology and expertise we put into your care, we maximise the potential of having a baby.
The Genea blog shares information, thoughts and advice with patients as well as those looking for all things fertility.
Follow our exciting and informative 10 part Modern Babies series presented by Genea and Nova
At Genea you will benefit from the work of the best specialists and science, which result in high success rates. Find the right specialist or the clinic that suits you today.
With locations throughout NSW, ACT, WA, New Zealand and beyond, find a Genea clinic which suits you; near work, or close to home.
The experience and science available to Genea’s Fertility Specialists result in high success rates. Browse the Genea Doctor directory now.
Search the list of Genea approved monitoring centres and find one close to your home or work.
Find the Genea locations where you can have a GeneSyte or other pathology testing done.
Find your closest Ovulation Tracking location.
If it's taking longer than you thought to have a baby, come to a free Genea fertility seminar and hear about your options.
Come along to hear local leading Fertility Specialist Dr Sonal Karia and learn more about the fertility process.
Come along to hear local leading Fertility Specialist Dr Anthony Marren explain the facts and dispel the fictions about egg freezing at a discussion at Sydney Westfield.
Come along to hear local leading Fertility Specialist Dr Matthew Holland and learn more about the fertility process.
Come along to hear local leading Fertility Specialists Dr Matthew Holland & Dr Ray Hodgson and learn more about the fertility process.
Genea's Pre-implantation Genetic Diagnosis scientists have helped hundreds of families achieve their dream of taking home a baby. We first launched chromosome testing of embryos in 1995 with gene testing introduced in 1998. Since then our PGD techniques have led the world.
Genea is one of the very few centres in Australia with the vital combination of IVF and genetics facilities to perform these sophisticated tests successfully. Genea was the first clinic in the world to perform blastocyst stage biopsy and we introduced it as routine in our labs in 2004. A review of information captured by the Australian and New Zealand Assisted Reproduction Database (ANZARD) between 2004 and 2008 showed our Day 5/6 biopsy approach to PGD resulted in a significant lift in IVF success rates and the number of babies born.
The data review showed blastocyst biopsy for PGD improves both implantation and live birth rates when compared to biopsy at Day 3. Since then, blastocyst stage biopsy has become a world standard - an innovation led by the Genea team. Learn more about Genea's PGD success rates.
Some couples also have non-random, inherited chromosomal abnormalities. We find that these sort of chromosomal rearrangements are 10 times more common in couples seeking IVF treatment and so this is why your Doctor may suggest that you have a simple blood test called a karyotype before you begin treatment. A karyotype (or picture of your chromosomes) helps us to identify most types of chromosome rearrangements in the parents prior to embryo testing, giving us a head start on the sorts of problems we need to look for in the embryos you create during your IVF cycle.
Because IVF is the starting point for any embryo testing, whether you are having a standard chromosome analysis, a gene specific test or a combination test, all of our processes have the same beginning.
Because DNA contamination from cumulus cells surrounding the egg or from unsuccessful sperm can contaminate PGD samples and result in misdiagnosis, we usually fertilise the egg using ICSI to reduce the likelihood of this problem occurring. Fertilisation with ICSI involves carefully removing the cumulus cells and then injecting a single sperm - both of which greatly reduces the risk of contamination.
At times there may be sound clinical reasons to use the alternative IVF insemination protocol and if this is the case for you and your partner, be assured your doctor is aiming at achieving the best possible outcome for you as a couple.
We identify correctly fertilised eggs by the presence of pronuclei on Day 1.
At some point during embryo development, we make a small hole in the outer layer of the embryo (the zona pellucida) using a delicate near infrared laser beam. Called assisted embryo hatching, this creation of a small slit (breach) in the zona helps promote the hatching of blastocysts on Days 5-6, a little earlier than would occur with IVF.
The embryo grows to form a blastocyst - a clump of cells (inner cell mass) inside a hollow ball of trophectoderm cells.
The expanding blastocyst, which is now 120-150 cells, hatches through the small breach that was created in the zona.
We then hold the hatching blastocysts with gentle suction and use a biopsy pipette to gently remove three to six trophectoderm cells (the cells that go on to become the placenta) usually with the assistance of the laser. These biopsied trophectoderm cells are now ready for testing. For total chromosome testing, the rest of the embryo is frozen to allow time for NGS or combined PCR/NGS analysis. If it is a PCR only test, then your Doctor will discuss with you your options to have either a fresh transfer after testing or a freeze-thaw transfer at a later time.
Vitrification is a freezing procedure that preserves embryos for future use.
To maximise survival, the embryos are partially dehydrated then snap frozen in liquid nitrogen.
At Genea our scientific team use two major types of tests or analysis:
This test checks all chromosomes to see if an embryo has a balanced set. It looks for:
The biopsied cells are washed and transferred into a reaction tube. We then extract the DNA and use enzymes to duplicate or amplify the three to six copies of the genome into approximately a million copies. This happens as a whole series of small DNA sections - it is important that the whole genome is represented in as even a profile as possible.
The amplified DNA is then modified to make it suitable for massively parallel sequencing (often referred to as Next Generation Sequencing or simply as NGS).
After sequencing the end of each DNA fragment, software can identify not only which chromosome the fragment belongs to but where on the chromosome it sits. Using mathematical comparisons, our software is then able to look and see if there are major imbalances amongst chromosomes or smaller parts along the chromosome. There is a limit to how small a piece can be analysed by this method but most of the common chromosome copy number changes can be identified. The software then plots the chromosome results onto a graph that can be interpreted by Scientists and reported to your Doctor. A profile of all 24 types of chromosome will assist the scientists to identify and avoid transferring any embryos with chromosome sets incompatible with either starting a pregnancy or getting to delivery successfully.
Image below: Illumina MiSeq sequencer provides NGS data for scientist to analyse
The chromosomes results are interpreted and reported to the doctor.
Image below: Example of normal male
Image below: Example of abnormal male
Suitable embryos, that is those that contain a balanced set of chromosomes, may be thawed and transferred. Don’t be concerned about this impacting your chance of success - our studies show that thawed embryos have implantation rates equal to or greater than fresh embryos.
Unfortunately, not all embryos are suitable for biopsy. They may however, be suitable for freezing or untested transfer.
An answer is achieved for most of the embryos tested. If for technical reasons we do not get an answer on an individual embryo, the genetic status of that embryo will be considered as unknown. These embryos may still be suitable for untested transfer, or potential thaw, rebiopsy and refreeze.
Embryos tested and deemed abnormal or affected are unsuitable for transfer.
You may complete a cycle and not have an embryo suitable for transfer.
The amplification of a few copies of DNA (from the few cells biopsied from an embryo) into millions of copies of DNA is at risk of contamination from extraneous human DNA as well as amplification biases. Despite our stringent precautions, there is always a small risk of contamination/bias resulting in a misdiagnosis.
Not all cells in an embryo may contain the same number of chromosomes, so the biopsy piece may not represent the whole embryo. NGS cannot detect low level Mosaicism (<50 per cent).
Image below: Example of mosaic male embryo (less than 100% of cells have lost a chromosome/chromosome segment)
For the above reasons, the accuracy of the test offered is 95 per cent.
Should you have prenatal diagnostic tests done?
As you have read above, PGD does not provide 100 per cent accuracy due to the various technical difficulties that can be experienced. We recommend that prenatal diagnostic tests are discussed with your referring doctor.
This test tracks the inheritance of specific small chromosomal regions associated with:
Polymerase chain reaction (PCR) is a molecular technique which amplifies a single copy or a few copies of a specific piece of DNA, generating thousands to millions of copies of a particular DNA sequence. Most PCR testing is done in combination with chromosome analysis (NGS), but PCR can also be done in isolation on 'fresh' embryos.
We wash the cells biopsied from the embryo and transfer them into a reaction tube before extracting their DNA. Because the biopsied cells do not contain enough DNA to analyse directly, PCR enzymes are used to duplicate or amplify specific small segments of the genome into millions of copies.
For single gene disorders, HLA matching and translocations we create or establish a unique PGD-PCR test for you as a family.
The screening process identifies informative linkage markers which we use to distinguish 'bad' mutation carrying chromosomes from the 'good' non-mutated chromosomes. Linkage markers are put together to form a mini DNA fingerprint that tells us whether the embryo has inherited the DNA mutation.
The primary test for all cases uses linkage markers which are small highly variable regions of DNA very near to the gene.
Where possible, a direct mutation test will also be included as backup confirmation.
PGD-PCR test workups take time to complete and must be finished before a cycle can commence.
Once the workup is completed, a PGD-PCR test can be used for the following:
Single Gene Disorders
For an embryo to be affected, a recessive disorder requires two copies of the mutated gene, one from each parent (as illustrated by the black peaks shown in the DNA linkage pattern below).
A dominant disorder requires just one copy of the mutated gene, inherited from an affected parent.
An X-linked disorder requires just one copy of the mutated gene, inherited from an affected parent (males are affected and females are typically unaffected carriers).
DNA linkage patterns can be used to check if an embryo is balanced for a specific translocation, is affected by UPD, and potentially determine if balanced embryos are carriers of a translocation or not.
Aneuploidy / Medical Sex Selection
The status for chromosomes X, Y and 21 of an embryo can be determined by looking at the DNA inheritance from both parents.
An answer is achieved for most of the embryos tested. If, for technical reasons, we do not get an answer on an individual embryo, the genetic status of that embryo will be considered as unknown. These embryos may still be suitable for transfer, freezing for future use, or if already frozen can potentially be thawed, rebiopsied and refrozen.
While we take stringent precautions to avoid DNA contamination, there is always a small risk that it may occur and if it does, it could result in a misdiagnosis. PCR will copy any DNA and any contamination present will contribute to the answer.
Other technical factors may contribute to loss of genetic information that might result in misinterpretation of the genetic status of the embryo. Technical limitations can also lead to a reduction in test accuracy. If this occurs during your treatment it will be discussed with you by your PGD scientist.
DNA may copy unevenly which could cause difficulty in interpreting the results for certain linkage markers. This is why the DNA fingerprint looks at multiple regions around the gene.
Chromosomes naturally rearrange their DNA during egg and sperm formation and this may affect the interpretation of the result. If a direct mutation test was able to be included, it may help resolve any interpretation problem.
After a PCR-only test is completed, a suitable embryo may be transferred later that day or frozen and then thawed for transfer at a future time, depending on what has been decided in conjunction with your Doctor. Embryos undergoing combined PCR/NGS testing will all be frozen for use in a future transfer.
Excess suitable embryos or those undergoing combined PCR/NGS testing can be preserved for future use by vitrification. Vitrification is a special freezing procedure during which we partially dehydrate the embryos before snap freezing them in liquid nitrogen.
As you’ve read above, PGD/PGS does not provide 100 per cent accuracy due to the various technical difficulties that can be experienced. We recommend that prenatal diagnostic tests are discussed with your referring doctor.
New technologies now mean we can combine both PCR and Chromosome testing on the one biopsy piece taken from your embryo - a second biopsy is not required to perform both analyses. As a result we can not only eliminate the risk from the inherited disorder but also ensure we exclude embryos that are chromosomally abnormal. This will allow better selection of embryos for transfer and help us achieve a healthy ongoing pregnancy faster.
As with total chromosome testing, embryos are vitrified after biopsy while the dual analysis is underway. Embryos that are identified as being disease gene free and chromosomally balanced are available for transfer on a subsequent freeze/thaw cycle.
Refer to Total Chromosome Analysis and Polymerase Chain Reaction (PCR) above for an in-depth explanation.
To conduct PGD or PGS, we biopsy or remove a small number of cells from each embryo for analysis. Don’t worry, this does not damage your precious embryos - at Genea, our advanced embryo culture techniques allow us to wait until the embryos have reached the blastocyst stage of development (Day 5 or 6). This means the embryos have a hundred or more cells and we need to remove on average three to six cells.
By waiting until embryos have reached the blastocyst stage, Genea scientists can select cells from the trophectoderm, the part of the embryo that will go on to form the placenta. The inner cell mass, the part that will become the baby, is not touched.
In contrast, many other clinics conduct the biopsy at Day 3 of the embryos' development when they consist of just six to eight cells. They remove one or two cells which may impact on the potential for the embryo to successfully implant in the uterus.
This explains the process at Genea:
1. At one point of the embryo's development, a small hole is made in the outer layer of the embryo (the zona pellucida) using a delicate laser beam.
2. The embryo continues development until Day 5 or 6 when it becomes a blastocyst, characterised by the separation of cells into trophoblasts (which go on to become the placenta) and the inner cell mass (which goes on to become the fetus).
3. Trophoblasts are drawn out through the hole using a hollow suction tube called a biopsy pipette. The required cells are separated from the others using the laser and collected separately.
4. The remaining cells quickly realign realign and seal the area from which the biopsied cells were removed.
Genea scientists use a number of different methods to analyse the biopsied cells.
For chromosome analysis, we use a technique called Next Generation Sequencing (NGS) to analyse biopsied cells.
To begin, the biopsied cells are subjected to whole genome amplification (WGA), a process that results in the production of multiple copies of all the chromosomes present.
Because NGS involves an extensive analysis procedure which takes some time, we vitrify or freeze all embryos undergoing chromosome analysis. Genea have been vitrifying Day 5/6 blastocysts clinically since January 2006 and there is no difference in success rates between fresh and frozen embryo transfers, so you can have confidence in this process.
Embryos that we find have a normal chromosome complement can then be transferred in subsequent frozen embryo cycles.
If the problem or condition we’re looking for is at a gene level rather than chromosome then we will use a technique called Polymerase Chain Reaction (PCR).
In the PCR process, we make millions of copies of a particular section of a gene region which allows us to see whether this part of the DNA in the sample carries the affected gene.